Patents by Inventor Shie-Ming Hwang

Shie-Ming Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6447797
    Abstract: It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula: wherein R1 and R2 are selected from the group consisting of hydrogen and monounsaturated and saturated fatty acids having a carbon chain length of C6 to C20 and R1 and R2 can be the same or different; and R3 to R7 are selected from the group consisting of hydrogen or a phosphate moiety with at least two of R3 to R7 being a phosphate moiety; and hydrates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: September 10, 2002
    Assignee: Abbott Laboratories
    Inventors: Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Pradip Mukerji, Steven Neal Anderson, Jonathan A. Meulbroek
  • Publication number: 20020106416
    Abstract: The attachment of H. influenzae to human cells such as oropharyngeal cells, is inhibited by aqueous extracts of the plants known as Pogostemon cablin and Agastache rugosa. The composition obtained from the aqueous extraction of the plants Pogostemon cablin, Agastache rugosa or mixtures thereof is also effective in preventing or treating Otitis media and sore throat. The plant extract may be contained in a liquid enteral product such as an infant formula or may be incorporated into lozenges, candies, chewing gums and the like. The plant extract may also be administered as a throat spray or nasally using drops or a spray. A process for the production of a medicinal product is also disclosed.
    Type: Application
    Filed: January 30, 2002
    Publication date: August 8, 2002
    Inventor: Shie-Ming Hwang
  • Publication number: 20010026806
    Abstract: It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans.
    Type: Application
    Filed: April 19, 2001
    Publication date: October 4, 2001
    Inventors: Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Pradip Mukerji, Steven Neal Anderson, Jonathan A. Meulbroek
  • Patent number: 6258375
    Abstract: It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula: wherein R1 and R2 are selected from the group consisting of hydrogen and monounsaturated and saturated fatty acids having a carbon chain length of C6 to C20 and R1 and R2 can be the same or different; and R3 to R7 are selected from the group consisting of hydrogen or a phosphate moiety with at least two of R3 to R7 being a phosphate moiety; and hydrates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: July 10, 2001
    Assignee: Abbott Laboratories
    Inventors: Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Pradip Mukerji, Steven Neal Anderson, Jonathan A. Meulbroek
  • Patent number: 6248372
    Abstract: The present invention is directed to a rice flour extract (RFE) which can be used in the prophylaxis and treatment of bacterial infections, particularly bacterial infections caused by Haemophilus influenzae and to a method of preparing and using such an antibacterial rice flour extract. The anti-Haemophilus influenzae rice flour extract of the present invention can be prepared from commercial food grade rice flours or non-commercial food grade rice flours.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: June 19, 2001
    Assignee: Abbott Laboratories
    Inventors: Pradip Mukerji, Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Steven Neal Anderson, Jonathan A. Meulbroek
  • Patent number: 6214350
    Abstract: This invention relates to compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to their use for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention arc derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitis C patients. Compositions according to the invention have also exhibited in vitro antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: April 10, 2001
    Inventor: Shie-Ming Hwang
  • Patent number: 5989556
    Abstract: Compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, are provided for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention are derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitis C patients. Compositions according to the invention have also exhibited in vitro antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses.
    Type: Grant
    Filed: July 9, 1997
    Date of Patent: November 23, 1999
    Assignee: Sage R&D
    Inventors: Hsiu-Hsien Tsai, Shie-Ming Hwang
  • Patent number: 5837257
    Abstract: This invention relates to compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to their use for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention are derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitic C patients. Compositions according to the invention have also exhibited in vitro antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: November 17, 1998
    Assignee: Sage R&D
    Inventors: Hsiu-Hsien Tsai, Shie-Ming Hwang, Pai-Chu Kung
  • Patent number: 5776462
    Abstract: The attachment of H. influenzae to human cells such as oropharyngeal cells, is inhibited by aqueous extracts of the plants known as Pogostemon cablin and Agastache rugosa. The composition obtained from the aqueous extraction of the plants Pogostemon cablin, Agastache rugosa or mixtures thereof is also effective in preventing or treating Otitis media and sore throat. The plant extract may be contained in a liquid enteral product such as an infant formula or may be incorporated into lozenges, candies, chewing gums and the like. The plant extract may also be administered as a throat spray or nasally using drops or a spray. A process for the production of a medicinal product is also disclosed.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: July 7, 1998
    Assignee: Sage R&D, a partnership
    Inventors: Hsiu-Hsien Tsai, Shie-Ming Hwang
  • Patent number: 5416077
    Abstract: There is disclosed liquid nutritionals with improved physical stability. The nutritionals are pourable yet able to hold minerals in suspension without sedimentation or sag. The invention comprises the use of iota-carrageenan of a concentration of between 50-1500 parts per million. The nutritional may also comprise kappa carrageenan at a concentration of less than 25% of the total concentration of iota- and kappa-carrageenan. There is further disclosed a method for preparing the liquid nutritional through the use of ultra-high temperature heat treatment.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: May 16, 1995
    Assignee: Abbott Laboratories
    Inventors: Shie-Ming Hwang, Timothy W. Schenz, James N. Chmura
  • Patent number: 5160742
    Abstract: A system for delivering an active substance has sustained release of the active substance in the intestinal tract. This delivery system is especially useful for an active substance such as a .beta.-lactam antibiotic which preferably has minimal exposure to the acidic environment of the stomach. Particles comprise an active ingredient disposed in a core which has at least one coating of a prolamine and one coating of an enteric compound thereon. The particles may be very small and suspended in a liquid medium.
    Type: Grant
    Filed: December 31, 1991
    Date of Patent: November 3, 1992
    Assignee: Abbott Laboratories
    Inventors: Terrence B. Mazer, Glenn A. Meyer, Shie-Ming Hwang, Edrick L. Candler, Jr., Lonnie R. Drayer, Andre Daab-Krzykowski